Hyperhomocysteinemia is an established risk factor for AD (27) and is experimentally associated with the development of hallmark pathological features of AD, including tau and APP phosphorylation, and amyloidogenesis (26). This evidence concerns the gene MAPT and hyperhomocysteinemia.